Business● LowSep 8 · Sep 8, 2026, 7:51 AM
Pharma major plummets over 10% after third trial disappointment in a week
GlobeAlert Desk · curated from CNBC · global
Shares of Novartis tanked on Tuesday after results from its del-desiran drug trial disappointed investors.
GlobeAlert aggregates and classifies open sources; the story above belongs to its publisher. Summaries are machine-generated from the source text. How we score stories.
GlobeAlert context
What the desk knows about this story
Threat level
1 Low
Scored from severity, scale, escalation potential and source agreement. Below the alert threshold.
Sources
1 publisher
Single-source so far. Treat details as unconfirmed until more publishers report.
Category
Business
Not flagged as developing.
More in Business
Business17m agoPayPal cut to Hold from Buy at Freedom Broker as Q3 branded checkout stalledSeeking Alpha TechBusiness22m agoFortis outlines $32.2B 5-year capital plan with 7.5% rate base CAGR and extends 4%-6% dividend growth through 2031Seeking Alpha TechBusiness24m agoSK Hynix in spotlight as Commerce Dept. holds up Chinese equipment plans: reportSeeking Alpha TechBusiness24m agoSotera Health reaffirms 2026 outlook, targets adjusted EPS of $0.95 to $1.01 amid European med device softnessSeeking Alpha Tech